271P Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan.
Saved in:
| Title: | 271P Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan. |
|---|---|
| Authors: | Wang, C.H.1, Lei, H.L.2, Borse, R.3, Chirovsky, D.3, Chien, L.2, Tan, S.C.4, Spiteri, C.5 |
| Source: | Annals of Oncology. 2020 Supplement 6, Vol. 31, pS1349-S1349. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.10.265 |
